Skip to main content

Advertisement

Log in

Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background No clear data are available concerning the superiority of combination chemotherapy to sequential therapy using agents beyond 1st or 2nd line chemotherapy for treating patients with metastatic breast cancer. Methods Patients were randomized to receive a combination of gemcitabine and vinorelbine or gemcitabine until disease progression followed by vinorelbine monotherapy. Quality of life was assessed using EORTC QLQ-C30 questionnaires. Results Forty-two patients were randomized to the combination arm and 40 were randomized to the sequential arm. Baseline characteristics were well balanced between the arms. The median number of chemotherapy cycles was 4 (range, 1–23) for the combination arm and 6 (range, 1–25) for the sequential arm. Patients receiving combination therapy had a higher composite response rate (26.8% vs. 12.5%; P = 0.106) but a shorter median time to treatment failure (3.6 vs. 4.4 months, P = 0.252) as compared to patients receiving sequential monotherapy. Median overall survival for the combination and sequential arms was 10.6 months and 8.9 months, respectively (P = 0.436). Toxicities were manageable and similar in both arms. Quality of life measurements in global health, role, and social function were superior in the combination arm (P < 0.05). Conclusions Combined gemcitabine and vinorelbine therapy appears comparable to sequential monotherapy for heavily pretreated patients with metastatic breast cancer as demonstrated by improved quality of life outcomes with similar therapeutic efficacies and incidences of adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Figgitt DP, Wiseman LR (2000) Docetaxel: an update of its use in advanced breast cancer. Drugs 59:621–651

    Article  CAS  PubMed  Google Scholar 

  2. Paridaens R, Biganzoli L, Bruning P et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724–733

    CAS  PubMed  Google Scholar 

  3. Michelotti A, Venturini M, Tibaldi C et al (2000) Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Res Treat 59:133–139

    Article  CAS  PubMed  Google Scholar 

  4. Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245–1252

    CAS  PubMed  Google Scholar 

  5. Carmichael J, Possinger K, Phillip P et al (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731–2736

    CAS  PubMed  Google Scholar 

  6. Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56–64

    Article  CAS  PubMed  Google Scholar 

  7. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493

    CAS  PubMed  Google Scholar 

  8. Livingston RB, Ellis GK, Gralow JR et al (1997) Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15:1395–1400

    CAS  PubMed  Google Scholar 

  9. Modi S, Currie VE, Seidman AD et al (2005) A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 6:55–60

    Article  CAS  PubMed  Google Scholar 

  10. O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823. doi:10.1200/JCO.2002.09.002

    Article  PubMed  Google Scholar 

  11. Albain KS, Nag SM, Calderillo-Ruiz G et al (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950–3957. doi:10.1200/JCO.2007.11.9362

    Article  PubMed  Google Scholar 

  12. Martin M, Ruiz A, Munoz M et al (2007) Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8:219–225. doi:10.1016/S1470-2045(07)70041-4

    Article  CAS  PubMed  Google Scholar 

  13. Miles D, von Minckwitz G, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13–19

    CAS  PubMed  Google Scholar 

  14. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  15. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  CAS  PubMed  Google Scholar 

  16. Yun YH, Park YS, Lee ES et al (2004) Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 13:863–868

    Article  CAS  PubMed  Google Scholar 

  17. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, EORTC Quality of Life Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organization for Research and Treatment of Cancer, Brussels

    Google Scholar 

  18. Mauri D, Polyzos NP, Salanti G et al (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100:1780–1791. doi:10.1093/jnci/djn414

    Article  CAS  PubMed  Google Scholar 

  19. Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31, 510 women. J Clin Oncol 16:3439–3460

    CAS  PubMed  Google Scholar 

  20. Zelek L, Barthier S, Riofrio M et al (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267–2272

    Article  CAS  PubMed  Google Scholar 

  21. Silvestris N, Cinieri S, La Torre I et al (2008) Role of gemcitabine in metastatic breast cancer patients: a short review. Breast 17:220–226. doi:10.1016/j.breast.2007.10.009

    Article  PubMed  Google Scholar 

  22. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592. doi:10.1200/JCO.2003.08.013

    Article  PubMed  Google Scholar 

  23. Morabito A, Filippelli G, Palmeri S et al (2003) The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I–II study. Breast Cancer Res Treat 78:29–36. doi:10.1023/A:1022197109592

    Article  CAS  PubMed  Google Scholar 

  24. Valenza R, Leonardi V, Gebbia V, Agostara B (2000) Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann Oncol 11:495–496

    Article  CAS  PubMed  Google Scholar 

  25. Stathopoulos GP, Rigatos SK, Pergantas N et al (2002) Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20:37–41

    Article  CAS  PubMed  Google Scholar 

  26. Modi S, Panageas KS, Duck ET et al (2002) Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 20:3665–3673. doi:10.1200/JCO.2002.08.057

    Article  CAS  PubMed  Google Scholar 

  27. Shin DB, Bang SM, Park SH et al (2008) Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors. Med Oncol 25:81–87. doi:10.1007/s12032-007-0045-5

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all participating patients and families.

This study was supported in part by NCC grant 0610240.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jungsil Ro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, I.H., Ro, J., Lee, K.S. et al. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Invest New Drugs 28, 659–669 (2010). https://doi.org/10.1007/s10637-009-9285-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9285-x

Keywords

Navigation